RNA Therapy Clinical Trials Market By Therapy Type (mRNA Therapy, siRNA Therapy, RNAi Therapy, Antisense Oligonucleotide Therapy), By Indication (Oncology, Genetic Disorders, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders), By Phase of Clinical Trials (Phase I, Phase II, Phase III, Phase IV), By End-User (Pharmaceutical Companies, Biotech Companies, Research Institutes, Contract Research Organizations), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the RNA Therapy Clinical Trials Market was valued at USD 2.9 Billion in 2024-e and will surpass USD 3.6 Billion by 2030; growing at a CAGR of 3.8% during 2025-2030.

The RNA therapy clinical trials market has witnessed substantial growth in recent years due to the rapid advancements in RNA-based therapeutic technologies. These therapies leverage RNA molecules, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides, to target specific genes and proteins responsible for diseases. With increasing investments in gene therapy research, regulatory approvals, and the promise of personalized medicine, the RNA therapy clinical trials market is expected to see continued expansion. This market encompasses a range of applications across several disease types and is being driven by the need for more effective treatments, particularly in oncology, genetic disorders, and infectious diseases.

mRNA Therapy Is Largest Owing to Its Successful Application in Vaccines

Among the various RNA therapies, mRNA therapy is the largest segment in the clinical trials market. mRNA therapy uses messenger RNA to instruct cells to produce proteins that can treat or prevent diseases. The most prominent example of mRNA therapy is the COVID-19 vaccines developed by Moderna and Pfizer, which showcased the potential of mRNA technology in rapidly addressing global health crises. Following the success of mRNA vaccines, there is growing interest in utilizing this platform for treating other infectious diseases, genetic disorders, and cancer.

The widespread use of mRNA vaccines has propelled the development of other mRNA-based therapies for conditions such as melanoma and cystic fibrosis. Companies are increasingly focusing on mRNA therapy to combat various infectious diseases, genetic mutations, and cancers, which is likely to drive the market’s growth in the coming years. The flexibility, speed of development, and adaptability of mRNA technology have made it a leading choice in clinical trials for diverse therapeutic applications.

Oncology Is Largest Owing to Expanding Application in Cancer Treatment

In terms of indications, oncology is the largest segment in RNA therapy clinical trials. Cancer remains one of the most pressing global health challenges, and the demand for innovative therapies to target cancer cells has prompted substantial research into RNA-based treatments. RNA therapies, particularly mRNA and RNA interference (RNAi), have shown significant promise in developing personalized cancer treatments by targeting the specific genes responsible for tumor growth.

RNA therapies are being developed to target key signaling pathways and tumor suppressor genes, offering the potential for more precise and effective treatments compared to traditional chemotherapy. Clinical trials focusing on oncology applications are seeing increased investments, particularly for mRNA-based cancer vaccines and RNAi therapies that can silence oncogenes and halt tumor progression. As the efficacy of RNA therapies in oncology continues to be demonstrated, this sector is expected to dominate the clinical trials market in the near future.

Phase II Is Fastest Growing Owing to Increasing Testing of Efficacy and Safety

In the phase of clinical trials segment, Phase II trials are the fastest growing owing to the critical role they play in evaluating the efficacy and safety of RNA therapies. While Phase I trials focus primarily on safety and optimal dosage, Phase II trials are essential in determining the therapeutic effect of a treatment and understanding its broader application to a wider patient population. For RNA therapies, Phase II trials often focus on validating the success seen in earlier phases and assessing how well the treatment works in combating diseases like cancer, genetic disorders, and infectious diseases.

The increasing number of RNA-based therapies moving into Phase II trials reflects the growing confidence in the technology and its potential applications. As more therapies move past initial safety testing, Phase II trials will remain a key area of focus for companies seeking to establish the clinical value of their RNA treatments. The results from these trials are vital for advancing RNA therapies to later-stage clinical trials and eventual commercialization.

Pharmaceutical Companies Are Largest Owing to Strong Investment in RNA Therapeutics

Pharmaceutical companies represent the largest end-user group in RNA therapy clinical trials. The increasing need for innovative treatments in oncology, genetic disorders, and infectious diseases has spurred pharmaceutical companies to invest heavily in RNA-based therapeutics. These companies are focusing on developing RNA therapies as a promising solution for diseases that currently have limited treatment options, such as rare genetic disorders and certain cancers. Pharmaceutical giants like Pfizer, Moderna, and Roche are leading the charge in integrating RNA technologies into their clinical pipelines.

The strategic partnerships between pharmaceutical companies and biotechnology firms are also enhancing the scope of RNA therapy clinical trials. These collaborations facilitate the sharing of expertise and resources, enabling pharmaceutical companies to advance RNA therapeutics faster through clinical stages. As these therapies continue to demonstrate their potential in clinical settings, pharmaceutical companies will remain at the forefront of RNA therapy trials, driving the market’s growth.

North America Is Largest Owing to Strong Research Infrastructure and Regulatory Environment

North America is the largest region in the RNA therapy clinical trials market. The region, particularly the United States, has a well-established healthcare infrastructure and is home to leading pharmaceutical and biotechnology companies. North America’s robust research environment, access to top-tier medical professionals, and significant investments in clinical trials have fostered a conducive environment for RNA-based therapies. Additionally, regulatory agencies such as the U.S. Food and Drug Administration (FDA) have provided accelerated pathways for the approval of RNA-based treatments, further encouraging clinical trials and their commercialization.

The region’s market dominance is also attributed to the high prevalence of diseases like cancer, neurological disorders, and genetic conditions, which are driving the demand for novel therapeutic solutions. North America’s leadership in RNA therapy clinical trials is expected to continue as the region remains a hub for research, development, and commercialization of RNA therapeutics.

Leading Companies and Competitive Landscape

The RNA therapy clinical trials market is highly competitive, with numerous players vying for leadership in developing RNA-based treatments. Key companies in this space include Moderna, Inc., Pfizer Inc., BioNTech SE, Alnylam Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., among others. These companies are driving the development of RNA therapies across various therapeutic areas, from oncology to genetic disorders. In addition to large pharmaceutical players, several biotech firms are innovating in RNA technology, focusing on niche applications and specialized RNA-based treatments.

The competitive landscape is characterized by intense research and development activities, partnerships, and mergers and acquisitions. Companies are forming alliances with academic institutions, biotechnology firms, and research organizations to advance RNA therapies through clinical trials and to tap into the growing market. With the increasing number of clinical trials and technological advancements, the market is expected to witness further consolidation and innovation in RNA-based therapeutics.

List of Leading Companies:

• Moderna, Inc.
• BioNTech SE
• Alnylam Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Translate Bio, Inc.
• CureVac AG
• Sanofi
• Pfizer Inc.
• Vertex Pharmaceuticals Incorporated
• Arcturus Therapeutics
• Sarepta Therapeutics
• Intellia Therapeutics, Inc.
• Regeneron Pharmaceuticals, Inc.
• Mendelian Therapeutics
• Editas Medicine, Inc.

Recent Developments:

• Both Moderna and Pfizer have received accelerated approvals for their mRNA COVID-19 vaccines, paving the way for the expanded use of mRNA technology in treating other diseases.
• Alnylam Pharmaceuticals has achieved significant milestones in RNA interference (RNAi) therapies, with their treatment for transthyretin amyloidosis showing promise in clinical trials.
• CureVac has entered into strategic partnerships to expand its mRNA vaccine platform, aiming to develop vaccines for infectious diseases beyond COVID-19.
• Sarepta Therapeutics has launched new clinical trials for gene therapies using RNA molecules to treat Duchenne muscular dystrophy, a rare genetic condition.
• Regeneron Pharmaceuticals has progressed one of its RNA-based cancer therapies into Phase III clinical trials, showing promising results in non-small cell lung cancer.

Report Scope: